Regeneron’s antibody drug both cleared and prevented coronavirus infections in a study in monkeys and hamsters. Another reason for optimism, infectious disease experts say, is that the antibody drugs developed by Regeneron and the National Institutes of Health were shown to be effective in the Ebola virus. Yet some researchers who expect antibody drugs to work in clinical trials are skeptical how much real-world impact they would then have. Doctors and health officials are looking to the drugs to fill a big gap in Covid-19 treatment. Regeneron expects to have the first data from its study of a monoclonal antibody in hospitalized and nonhospitalized patients by the end of September.

Source: Wall Street Journal August 23, 2020 14:48 UTC